High NOTCH activity induces radiation resistance in non small cell lung cancer

Jan Theys1, Sanaz Yahyanejad1, Roger Habets1

  • 1Department of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center (MUMC+).

Abstract

Insights

High NOTCH pathway activity in non-small cell lung cancer (NSCLC) correlates with poor prognosis and radiation resistance. Blocking NOTCH may improve radiotherapy outcomes for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The NOTCH pathway is crucial for lung development but often dysregulated in non-small cell lung cancer (NSCLC).
  • High NOTCH activity is implicated as a potential driver of therapeutic resistance in various cancers.

Purpose of the Study:

  • To investigate the role of NOTCH signaling in NSCLC.
  • To determine if high NOTCH activity contributes to resistance against radiotherapy in NSCLC.

Main Methods:

  • Quantitative RT-PCR analyzed NOTCH signaling in NSCLC patient samples.
  • In vitro clonogenic assays assessed radiation sensitivity of NSCLC cells with manipulated NOTCH activity.
  • In vivo xenograft models evaluated tumor response to irradiation and microenvironmental factors.

Main Results:

  • Patients with high tumor NOTCH activity exhibited significantly worse disease-free survival.
  • While NOTCH activity did not alter intrinsic radiosensitivity in vitro, blocking it slowed xenograft tumor growth.
  • High NOTCH activity was associated with faster tumor growth, increased hypoxia, and radioresistance in vivo.

Conclusions:

  • NOTCH signaling plays a significant role in NSCLC tumor progression and radioresistance.
  • High NOTCH activity is a biomarker for poor prognosis in NSCLC patients.
  • Targeting NOTCH signaling presents a potential therapeutic strategy to enhance radiotherapy efficacy in NSCLC.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...